Full text is available at the source.
Abstract
Synthetic PPARγ agonists are being explored for their therapeutic potential in various human disorders.
- PPARγ regulates genes involved in glucose management.
- Diverse synthetic PPARγ agonists, including thiazolidinediones and non-thiazolidinediones, are being developed.
- Recent advances highlight therapeutic applications in type 2 diabetes, liver and inflammatory diseases, cancer, and neurological disorders.
- Studies utilizing cellular, animal models, and clinical trials have been conducted over the past decade.
Simplified